This yr’s J.P. Morgan Healthcare Convention in San Francisco, which wrapped on Thursday, enabled healthcare leaders from all around the nation to convene, have discussions and community. The occasion additionally featured a slew of stories bulletins from firms all around the healthcare sector.
Beneath are seven notable bulletins made through the convention.
Mayo Clinic forges AI collaboration with Cerebras Methods
Mayo Clinic launched a partnership with Silicon Valley-based AI agency Cerebras Methods to develop new AI fashions for healthcare use circumstances. Mayo plans to use Cerebras’ computing chips and methods to the well being system’s wealth of anonymized medical information and information, which spans a number of a long time.
The well being system mentioned that the AI fashions developed below this partnership will carry out quite a lot of capabilities. For instance, some instruments will be capable to generate summaries of key data from new sufferers’ medical information. Others might be able to rapidly study genome information or scrutinize medical pictures to determine patterns which will elude the human eyes of skilled medical professionals.
Mayo famous these new AI fashions is not going to make medical choices, because the accountability for such judgments will proceed to relaxation with docs. The brand new fashions will ultimately turn out to be obtainable on Mayo Clinic Platform, an information community utilized by well being methods within the U.S. and overseas.
Boston Scientific to accumulate Axonics for $3.7 billion
Boston Scientific introduced its plan to accumulate Axonics, a maker of neurostimulation units that deal with urinary and bowel dysfunction, for $3.7 billion. Specialists agree that this deal will make a worthwhile impression on Boston Scientific’s urology enterprise.
Axonics presents each rechargeable and recharge-free implants for sacral neuromodulation — a minimally invasive process that treats overactive bladder and bowel incontinence. The sort of remedy delivers gentle electrical pulses to the sacral nerves, which management the bladder, bowel and pelvic ground muscle groups. This modulation helps regulate and normalize nerve signaling — resulting in improved coordination of bladder and bowel actions, lowered urinary incontinence and alleviation of signs related to pelvic ground dysfunction.
The deal is the newest in a string of acquisitions Boston Scientific has made prior to now two years. In 2022, the corporate introduced acquisitions of hydrogel maker Obsidio, endoscopy gadget producer Apollo Endosurgery and cardiovascular remedy gadget firm Acotec Scientific. Final yr, the corporate purchased Relievant Medsystems, which makes units for power again ache.
Amazon launches a program selling digital well being advantages
Amazon rolled out a new initiative to assist join individuals to digital well being advantages that they might not know can be found to them via their employer or well being plan. To take action, Amazon plans to companion with digital well being firms providing applications that assist handle power circumstances like diabetes and hypertension.
Amazon’s first companion for this new program is Omada Well being — a San Francisco-based startup that gives digital look after diabetes prevention, weight administration, diabetes and hypertension.
When Amazon clients seek for a tool like a blood stress monitor or blood glucose meter, they may see a notification alerting them that they could be eligible to hitch a power situation administration program for gratis. Customers can then go to the Amazon Well being webpage to examine if their employer or well being plan has made Omada’s applications obtainable to them. In the event that they want to take part, Amazon will information them to Omada’s web site to finish their enrollment.
U.S. staff go away about 30% of their whole compensation on the desk by not using the advantages which are obtainable to them, Amazon identified in its announcement.
Johnson & Johnson to purchase Ambrx for $2 billion
Johnson & Johnson reached a $2 billion deal to accumulate clinical-stage Ambrx Biopharma. The deal is without doubt one of the many acquisitions that huge pharmaceutical firms have made prior to now few years within the antibody drug conjugate (ADC) house.
ADCs are a well-liked goal for pharma acquisitions as a result of they boast promising potential to make most cancers remedy simpler. These medicine ship poisonous payloads on to most cancers cells, aiming to reduce harm to wholesome cells and enhance precision when attacking tumors.
Ambrx’s lead program targets the protein PSMA and is at the moment in Section 1 testing for superior prostate most cancers. In November, the corporate reported promising information from a dose-escalation examine and mentioned it expects to have a beneficial dose for Section 2 testing in early 2024.
Abbott’s diabetes care unit declares first insulin pump integration within the U.S.
Abbott’s diabetes care enterprise introduced the mixing of its FreeStyle Libre 2 Plus steady glucose monitor into Tandem Diabetes Care’s t:slim X2 insulin pump.
Abbott’s up to date steady glucose monitor was cleared by the FDA to be used with automated insulin supply in March of final yr. The JPM announcement marks the primary automated insulin supply system to combine Abbott’s new FreeStyle Libre 2 Plus sensor.
This announcement comes a month after Tandem grew to become the primary firm to combine with Dexcom’s newest steady glucose monitor.
Merck buys Harpoon Therapeutics for $680 million
Merck introduced that it’s going to purchase Harpoon Therapeutics, a developer of focused most cancers therapies, for $680 million. Harpoon conducts analysis on T cell engagers, a class of medicine that activate T cells to kill most cancers cells.
Not like typical T cell engagers, Harpoon’s medicine not solely bind to a T cell and a most cancers cell, but in addition incorporate a site that extends the remedy’s half-life. The corporate’s lead drug candidate is designed to focus on DLL3, a most cancers protein expressed at excessive ranges in small cell lung most cancers and neuroendocrine tumors. The drug is in Section 1/2 testing as a monotherapy in sufferers with superior cancers that categorical the DLL3 protein.
Innovaccer launches generative AI-based medical documentation device
Innovaccer unveiled Sara Scribe, an AI resolution designed to fight skilled burnout. The AI assistant transcribes after which summarizes key data from the conversations held between suppliers and sufferers.
The device not solely analyzes patient-provider conversations — it additionally guarantees to make use of EHR and claims information to flag potential coding gaps, high quality gaps and diagnoses.
Picture: Getty Photos, Digital Imaginative and prescient
